PAST
CONFERENCES: 2004
The
Discovery Science and Biotechnology Meeting:
DSB 2004 Meeting ~ May 5-7, 2004, Dockside, Cockle Bay Wharf,
Sydney, Australia
International invited Speakers:
- Associate Professor Tony Buss, President & CEO, MerLion
Pharmaceuticals
- Dr Seth Grant, Sanger
Institute
- Dr Gábor Lamm, EMBLEM,
Heidelberg
- Professor Edison Liu, Genome Institute,
Singapore
- Dr
Julia Wulfkuhle, NIH,
Bethesda, Maryland
Sessions and Speakers included:
Session 1: Personalised medicine and nanotechnology
- Edison Liu, Genome Institute, Singapore
Gene profiling in breast cancer
- Matt Trau, The University of Queensland
Drug & Gene Nano-Balls: Applications of Nanotechnology
in Genomics, Proteomics, Drug Discovery and Diagnostics
- Rob Sutherland, Garvan
Institute of Medical Research
Identification of new prognostic markers and therapeutic targets for prostate
cancer through genome wide transcript profiling
Session 2: Genomics and functional genomics - Sponsored
by: MILLENNIUM SCIENCE
- David Martin, Victor
Chang Cardiac Research Institute, Sydney
Germline epimutations in human disease
- Peter Little, UNSW
Genetic variation and the control of transcription
- Dick Cotton, St
Vincent's Hospital Melbourne
The problem of collecting all mutations causing inherited disease
- Gene Tanimoto, Affymetrix/Millennium
Science
The power of the Probe Set: What’s in store for your next Affymetrix Microarray
experiment?
Session 3: Bioinformatics
- Marc Wilkins, Proteome
Systems
Bioinformatics for proteomics: algorithms,
integration and visualisation
- Mark
Ragan, IMB, Queensland
High-throughput bioinformatics: automating the
search for lateral gene transfer
Session 4: Proteomics - Sponsored
by: BECKMAN COULTER
- Julia Wulfkuhle, Clinical
Proteomics Program, NIH, Bethesda, Maryland
Protein microarrays: Molecular profiling technologies
for diagnosis and monitoring of cancer
- Tony Weiss, Sydney
University
Proteomics of linked tropoelastin multimers
- Stuart Cordwell and Melanie White, APAF
- Duncan Veal, FLUOROtechnics,
Sydney
Fluorescent Tools in Proteomics
Session 5: From Research to Retail -
Sponsored by: AUSTRALIAN LIFE SCIENTIST
- Stephen Livesey, NSCC,
Melbourne
From concept to profitability- One perspective
- Greg Collier, Deakin
University
AGT Biosciences from Genomics to Therapeutics
Session 6: Natural products and biodiversity -
Sponsored by: ASTRA ZENECA
- Tony Buss, Merlion
Pharma, Singapore
A New Model for Utilising Chemical Diversity from
Natural Products
- Paul Alewood, University
of Queensland
Venoms to drugs
- Rohan Davis, Griffith
University, QLD
Bioactive Secondary Metabolites from Endophytic Fungi
Session 7: Cancer genomics and proteomics
- Jane Armes, University
of Melbourne
Genotype-Phenotype correlations in breast cancer
- Susan Clark, Sydney
Cancer Institute
DNA methylation and gene silencing in cancer
- Mark Waltham, St. Vincent's
Institute of Medical Research, Melbourne
Gene expression profiling cancer models of epithelial-to-mesenchymal
transition
- Rob Baxter, Kolling
Institute, Sydney
SELDI-TOF in cell biology and diagnostics
Session 8: Protecting and commercialising innovation -
Sponsored by: GRIFFITH HACK
- Gábor Lamm, EMBLEM,
Heidelberg
Turning Ideas into Products: The Innovation Process
at EMBL
- Richard Jefferson, CAMBIA
The BIOS initiative - open source biology
- Vivien Santer, Griffith Hack
Biotechnology Patents- Changes on the Horizon?
Session 9: Brain development and diseases
- Peter Schofield, Garvan
Institute of Medical Research
Genetic polymorphism (Val66Met) in brain derived growth factor
gene associated with deficits in episodic and working memory in humans
- Brian Dean, Mental
Health Research Institute of Victoria
Combining genomics and proteomics to understand
the pathologies of psychiatric illnesses.
- Marko Premzl, RSBS,
ANU
The prion protein gene: detecting regulatory signals using tammar wallaby sequence
|
